Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
[There is evidence for the use of cannabinoids for symptomatic treatment of multiple sclerosis].
Changes of brain resting state functional connectivity predict the persistence of cognitive rehabilitation effects in patients with multiple sclerosis.
Purinergic signalling in the urinary tract in health and disease.
Assessing humoral immunocompetence after alemtuzumab treatment in MS.
Hes3 expression in the adult mouse brain is regulated during demyelination and remyelination.
Sialic acid-modified antigens impose tolerance via inhibition of T-cell proliferation and de novo induction of regulatory T cells.
Mutant huntingtin downregulates myelin regulatory factor-mediated myelin gene expression and affects mature oligodendrocytes.
Functional connectivity changes within specific networks parallel the clinical evolution of multiple sclerosis.
Depression and hypomania symptoms are associated with high dose corticosteroids treatment for MS relapses.
Role of executive functions in prospective memory in multiple sclerosis: Impact of the strength of cue-action association.
Metabolite Changes in Normal Appearing Cervical Spinal Cord in Two Patients with Multiple Sclerosis. A Proton MR Spectroscopic Analysis.
Recent Advances in Monoclonal Antibody Therapies for Multiple Sclerosis.
Non-myeloablative autologous haematopoietic stem cell transplantation expands regulatory cells and depletes IL-17 producing mucosal-associated invariant T cells in multiple sclerosis.
Antibody Recognition In Multiple Sclerosis And Rett Syndrome Using A Collection Of Linear And Cyclic N-glucosylated antigenic probes.
B cells from relapsing remitting multiple sclerosis patients support neuro-antigen-specific Th17 responses.
Passively transferred human NMO-IgG exacerbates demyelination in mouse experimental autoimmune encephalomyelitis.
Comparison of Compliance And Discontinuation Rates Among Ms Patients Treated With Fingolimod and Other Disease-Modifying Therapies: A Canadian Retrospective Claims Analysis.
Vaccines in Multiple Sclerosis.
Exploration of high-density protein microarrays for antibody validation and autoimmunity profiling.
Sodium chloride inhibits the suppressive function of FOXP3+ regulatory T cells.
Multiple sclerosis or neurological manifestations of Celiac disease.
Direct visualization of short transverse relaxation time component (ViSTa).
Neuropathology of JC virus infection in progressive multifocal leukoencephalopathy in remission.
Us Rrms Patient Preferences for Multiple Sclerosis Treatments: An Online Survey.
Chemotactic signaling and beyond: link between interleukin-16 and axonal degeneration in multiple sclerosis.
Pages
« first
‹ previous
…
663
664
665
666
667
668
669
670
671
…
next ›
last »